Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Empagliflozin/Linagliptin/Metformin HCl ER Tablets vs Trijardy XR
NCT07872358Phase 1Completed
- Sponsor
- Humanis
- Start
- Jun 2026
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empagliflozin, linagliptin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Humanis. Primary endpoints: Maximum concentration obtained at 72 hours, Area under the plasma concentration-time curve from time 0 to last collection time at 48 hours and 1 more. Started Jun 2026; status: completed.
02
Drugs
empagliflozinlinagliptinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07872358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07872358.